Exploring the benefits and limits of highly active antiretroviral therapy.
D'Aquila
R
R
Walker
B
B
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000235:genetics* / Q000502:physiology; D006801:Humans; D012367:RNA, Viral / Q000032:analysis*; D019562:Viral Load; D014766:Viremia; D014779:Virus Replication
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D012367:RNA, Viral